Trial Profile
Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia-The PROGRESS Pilot Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 May 2023
Price :
$35
*
At a glance
- Drugs Hydroxyprogesterone (Primary)
- Indications Preeclampsia
- Focus Therapeutic Use
- Acronyms PROGRESS
- 05 Jan 2022 Planned End Date changed from 31 Jan 2022 to 31 Jan 2024.
- 05 Jan 2022 Planned primary completion date changed from 30 Jan 2022 to 31 Jan 2024.
- 01 Jun 2021 Planned End Date changed from 31 Jan 2020 to 31 Jan 2022.